

# Luis J Montaner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/382593/publications.pdf>

Version: 2024-02-01

52  
papers

2,753  
citations

279798

23  
h-index

189892

50  
g-index

57  
all docs

57  
docs citations

57  
times ranked

4411  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Minority Scientists™ Experience: Challenging and Overcoming Barriers to Enhancing Diversity and Career Advancement. <i>Journal of Immunology</i> , 2022, 208, 197-202.	0.8	2
2	Preliminary Acceptability of a Home-Based Peripheral Blood Collection Device for Viral Load Testing in the Context of Analytical Treatment Interruptions in HIV Cure Trials: Results from a Nationwide Survey in the United States. <i>Journal of Personalized Medicine</i> , 2022, 12, 231.	2.5	6
3	Use of hyphenated analytical techniques to identify the bioactive constituents of <i>Gunnera perpensa</i> L., a South African medicinal plant, which potently inhibit SARS-CoV-2 spike glycoprotein–host ACE2 binding. <i>Analytical and Bioanalytical Chemistry</i> , 2022, 414, 3971-3985.	3.7	5
4	Persons who inject drugs (PWID) retain functional NK cells, dendritic cell stimulation, and adaptive immune recall responses despite prolonged opioid use. <i>Journal of Leukocyte Biology</i> , 2021, 110, 385-396.	3.3	3
5	Intact Human Immunodeficiency Virus (HIV) Reservoir Estimated by the Intact Proviral DNA Assay Correlates With Levels of Total and Integrated DNA in the Blood During Suppressive Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2021, 72, 495-498.	5.8	23
6	Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. <i>Nature Communications</i> , 2021, 12, 346.	12.8	107
7	Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption. <i>MBio</i> , 2021, 12, .	4.1	15
8	Increased Proviral DNA in Circulating Cells Correlates with Plasma Viral Rebound in Simian Immunodeficiency Virus-Infected Rhesus Macaques after Antiretroviral Therapy Interruption. <i>Journal of Virology</i> , 2021, 95, .	3.4	5
9	Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV. <i>Nature Communications</i> , 2021, 12, 3922.	12.8	31
10	BCL6 BTB-specific inhibitor reversely represses T <sub>H</sub> cell activation, T <sub>H</sub> cells differentiation, and germinal center reaction in vivo. <i>European Journal of Immunology</i> , 2021, 51, 2441-2451.	2.9	6
11	The Natural Stilbenoid (–)-Hopeaphenol Inhibits Cellular Entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7, and B.1.351 Variants. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0077221.	3.2	26
12	Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	54
13	BCL6 BTB-specific inhibition via FX1 treatment reduces T <sub>H</sub> cells and reverses lymphoid follicle hyperplasia in Indian rhesus macaque ( <i>Macaca mulatta</i> ). <i>Journal of Medical Primatology</i> , 2020, 49, 26-33.	0.6	5
14	Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 18692-18700.	7.1	67
15	Hepatitis C virus modulates IgG glycosylation in HIV co-infected antiretroviral therapy suppressed individuals. <i>Aids</i> , 2020, 34, 1461-1466.	2.2	2
16	Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 32066-32077.	7.1	44
17	Effect of Opioid Use on Immune Activation and HIV Persistence on ART. <i>Journal of NeuroImmune Pharmacology</i> , 2020, 15, 643-657.	4.1	9
18	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. <i>Nature Medicine</i> , 2020, 26, 1339-1350.	30.7	96

#	ARTICLE	IF	CITATIONS
19	Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. <i>Journal of Leukocyte Biology</i> , 2020, 108, 17-41.	3.3	573
20	Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint. <i>Aids</i> , 2020, 34, 681-686.	2.2	26
21	Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer. <i>Cell Reports</i> , 2020, 33, 108571.	6.4	99
22	Repeated semen exposure decreases cervicovaginal SIVmac251 infection in rhesus macaques. <i>Nature Communications</i> , 2019, 10, 3753.	12.8	3
23	NK Response Correlates with HIV Decrease in Pegylated IFN- $\gamma$ -Treated Antiretroviral Therapy-Suppressed Subjects. <i>Journal of Immunology</i> , 2019, 203, 705-717.	0.8	16
24	Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting. <i>Lancet HIV</i> , 2019, 6, e259-e268.	4.7	139
25	S100A14 Is Increased in Activated NK Cells and Plasma of HIV-Exposed Seronegative People Who Inject Drugs and Promotes Monocyte-NK Crosstalk. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 234-241.	2.1	5
26	BCL6 Inhibitor-Mediated Downregulation of Phosphorylated SAMHD1 and T Cell Activation Are Associated with Decreased HIV Infection and Reactivation. <i>Journal of Virology</i> , 2019, 93, .	3.4	11
27	Gene expression profiling informs HPV cervical histopathology but not recurrence/relapse after LEEP in ART-suppressed HIV+HPV+ women. <i>Carcinogenesis</i> , 2019, 40, 225-233.	2.8	5
28	CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	105
29	Anti- $\beta$ 27 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	65
30	Quantitation of Integrated HIV Provirus by Pulsed-Field Gel Electrophoresis and Droplet Digital PCR. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	15
31	A20 upregulation during treated HIV disease is associated with intestinal epithelial cell recovery and function. <i>PLoS Pathogens</i> , 2018, 14, e1006806.	4.7	12
32	The role of CD32 during HIV-1 infection. <i>Nature</i> , 2018, 561, E17-E19.	27.8	43
33	HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy-treated HIV/HCV-infected subjects. <i>Journal of Viral Hepatitis</i> , 2017, 24, 865-876.	2.0	8
34	BCL6 represses antiviral resistance in follicular T helper cells. <i>Journal of Leukocyte Biology</i> , 2017, 102, 527-536.	3.3	21
35	IFN- $\gamma$ augments natural killer-mediated antibody-dependent cellular cytotoxicity of HIV-1-infected autologous CD4+ T cells regardless of major histocompatibility complex class I downregulation. <i>Aids</i> , 2017, 31, 613-622.	2.2	22
36	HIV-1-negative female sex workers sustain high cervical IFN $\gamma$ , low immune activation, and low expression of HIV-1-required host genes. <i>Mucosal Immunology</i> , 2016, 9, 1027-1038.	6.0	28

#	ARTICLE	IF	CITATIONS
37	Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm <sup>3</sup> results in differential recovery of monocyte activation. <i>Journal of Leukocyte Biology</i> , 2016, 100, 223-231.	3.3	10
38	Plasmacytoid dendritic cell and functional HIV-1 Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV-1 viral load after treatment interruption in chronically suppressed HIV-1 patients. <i>Immunology</i> , 2015, 145, 380-390.	4.4	10
39	Innate Activation of MDC and NK Cells in High-Risk HIV-1-Exposed Seronegative IV-Drug Users Who Share Needles When Compared With Low-Risk Nonsharing IV-Drug User Controls. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 264-273.	2.1	23
40	Serial Cervicovaginal Exposures With Replication-Deficient SIVsm Induce Higher Dendritic Cell (pDC) and CD4+ T-Cell Infiltrates Not Associated With Prevention but a More Severe SIVmac251 Infection of Rhesus Macaques. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 405-413.	2.1	9
41	A Correlate of HIV-1 Control Consisting of Both Innate and Adaptive Immune Parameters Best Predicts Viral Load by Multivariable Analysis in HIV-1 Infected Viremic Controllers and Chronically-Infected Non-Controllers. <i>PLoS ONE</i> , 2014, 9, e103209.	2.5	17
42	Pegylated Interferon Alfa-2a Monotherapy Results in Suppression of HIV Type 1 Replication and Decreased Cell-Associated HIV DNA Integration. <i>Journal of Infectious Diseases</i> , 2013, 207, 213-222.	4.0	183
43	Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)-1 highly exposed seronegative subjects (HESN). <i>Clinical and Experimental Immunology</i> , 2011, 164, 158-169.	2.6	79
44	Increased plasmacytoid dendritic cell maturation and natural killer cell activation in HIV-1 exposed, uninfected intravenous drug users. <i>Aids</i> , 2010, 24, 2151-2160.	2.2	33
45	Retention of viability, cytotoxicity, and response to IL-2, IL-15, or IFN- $\gamma$ by human NK cells after CD107a degranulation. <i>Journal of Leukocyte Biology</i> , 2009, 85, 871-876.	3.3	22
46	Baseline Viral Load and Immune Activation Determine the Extent of Reconstitution of Innate Immune Effectors in HIV-1-Infected Subjects Undergoing Antiretroviral Treatment. <i>Journal of Immunology</i> , 2007, 179, 2642-2650.	0.8	75
47	NK Cell Lysis of HIV-1-Infected Autologous CD4 Primary T Cells: Requirement for IFN-Mediated NK Activation by Plasmacytoid Dendritic Cells. <i>Journal of Immunology</i> , 2007, 179, 2097-2104.	0.8	50
48	Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cells. <i>Aids</i> , 2007, 21, 293-305.	2.2	25
49	Randomized, Controlled Trial of Therapy Interruption in Chronic HIV-1 Infection. <i>PLoS Medicine</i> , 2004, 1, e64.	8.4	67
50	Persistent Decreases in Blood Plasmacytoid Dendritic Cell Number and Function Despite Effective Highly Active Antiretroviral Therapy and Increased Blood Myeloid Dendritic Cells in HIV-Infected Individuals. <i>Journal of Immunology</i> , 2002, 168, 4796-4801.	0.8	309
51	CCR5 and CXCR4 expression correlated with X4 and R5 HIV-1 infection yet not sustained replication in Th1 and Th2 cells. <i>Aids</i> , 2001, 15, 1941-1949.	2.2	31
52	Enhancement of Human Immunodeficiency Virus Type 1-Specific CD4 and CD8 T Cell Responses in Chronically Infected Persons after Temporary Treatment Interruption. <i>Journal of Infectious Diseases</i> , 2000, 182, 766-775.	4.0	108